SECL organizes first 'Sneh Milan Mela to build stronger Community Relations (See 'Corp Brief') A&C - Eviction of tenants governed by Rent Control Act can't be sought u/s 9 of Arbitration & Conciliation Act, particularly if they are not parties to Development Agreement executed between Developer and Landlords: HC See 'Legal Desk') IBC - Details and additional explanation provided by Mr. Akash Shinghal is insufficient to justify alleged legal fees incurred by him which leads to suspesion of registration: IBBI See 'Legal Desk') MoU for deepening cooperation & peace as enshrined in teachings of Buddha (See 'Corp Brief') Reddy launches Website to strengthen Non-Ferrous Metal Recycling Ecosystem (See 'Corp Brief') C-DOT & CSIR-NPL sign MoU for research in Classical & Quantum Communications (See 'Corp Brief') SARFAESI - provisions of Section 14 of the Act mandatorily require DM to consider an application filed u/s 14 of the Act, within 30 days' time: HC (See 'Legal Desk') ECI crosses milestone of training over 2,300 field-level election functionaries (See 'Corp Brief') Central Council for Research in Ayurvedic Sciences revives 2 rare Ayurvedic manuscripts (See 'Corp Brief') IBC - Mere stamping of tax invoices at site office only indicates receipt and doesn't imply acceptance by Corporate Debtor (CD) that there was no pre-existing dispute with respect to quantum of amount payable by CD to Operational Creditor: NCLAT (See 'Legal Desk') PM Modi invites PM Starmer to visit India (See 'Corp Brief') India set to welcome 1800+ global delegates at Yashobhoomi for Space Conference (See 'Corp Brief') Insolvency and Bankruptcy Code- Mr. Kuldeep Verma had charged fees and expenses exceeding regulatory limits and these charges were not supported by requisite approvals : IBBI (See 'Legal Desk') Rijiju meets President of Vietnam Luong Cuong (See 'Corp Brief') IBC - Mr. Anil Kumar Mittal's failure to actively engage and expedite withdrawal process has resulted undue delays in withdrawal process : IBBI (See 'Legal Desk') DFS Secy reviews performance of RRBs (See 'Corp Brief') MoS visits Eastern Coalfields Limited (See 'Corp Brief') BIMSTEC and global experts meet to shape Ethical, Inclusive AI Standards (See 'Corp Brief') IBC - Proceedings u/s 138 of N I Act for dishnonour of cheque can't continue against individuals once moratorium u/s 14 of IBC is in effect: HC (See 'Legal Desk') MICE tourism is recognized as key driver for economic growth (See 'Corp Brief') Prakash Magdum assumes charge as Managing Director, NFDC (See 'Corp Brief') MoS calls for AI-led innovations (See 'Corp Brief') A&C - Procedural order given by Arbitral Tribunal, such as rejecting application seeking impleadment of party, does not qualify as interim award: HC (See 'Legal Desk') A Landmark Ruling Reshaping the IBC Framework (See CORP EINSICHT) APEDA calls stakeholders for Chintan Shivir (See 'Corp Brief') MoS for Coal and Mines reviews performance of CMPDI (See 'Corp Brief') A&C - Once arbitral tribunal is constituted, all jurisdictional and factual issues including status of non-signatories should be resolved by tribunal, not by courts, except under limited scope of review permitted by Sec 34: SC (See 'Legal Desk') WAVES as platform amplifies creative synergy between global and Indian storytellers: Co-CEO of Netflix (See 'Corp Brief') 'Driving Innovation with IP' workshop held at IISc (See 'Corp Brief') IBC - PMLA being Public Law, NCLAT did not have any power or jurisdiction to review decision of Statutory Authority under PMLA: SC (See 'Legal Desk') IICT launches strategic collaborations with Industry Leaders (See 'Corp Brief') Trade Mark Act - Defendants are trying to ruin goodwill established by plaintiffs in their CHOTIWALA trademarks and artistic works : HC (See 'Legal Desk') Mandaviya inaugurates Khelo India Multipurpose Hall in Arunachal (See 'Corp Brief') PMLA - Insolvency and Bankruptcy Code, 2016 does not affect proceedings under Prevention of Money Laundering Act, 2002 : TRIBUNAL (See 'Legal Desk')

Print

Govt hosts workshop on increasing R&D in pharma-medical tech sector

Published: Mar 13, 2025

By TIOLCorplaws News Service

NEW DELHI, MAR 13, 2025: THE Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India, organised a workshop on the Promotion of Research and Innovation in Pharma-MedTech Sector (PRIP) Scheme today. The workshop was inaugurated in the presence of the Secretaries of five stakeholder Ministries and Departments of the Government of India, namely, Amit Agrawal, Secretary, Department of Pharmaceuticals; Prof. Abhay Karandikar, Secretary, Department of Science and Technology (DST); S. Krishnan, Secretary, Ministry of Electronics and Information Technology (MeitY); Dr N. Kalaiselvi, Secretary, Department of Scientific and Industrial Research (DSIR) and Director General (DG), Council of Scientific and Industrial Research (CSIR); and Dr Rajiv Bahl, Secretary, Department of Health Research (DHR) and DG, Indian Council for Medical Research (ICMR). The workshop served as a platform for identifying key action points and approaches to further the shared commitment to promote research and development in the pharmaceuticals and medical technologies sector.

Amit Agrawal, Secretary, Department of Pharmaceuticals highlighted the rapid expansion in the sector, underscoring the importance of research and innovation in driving making and innovating in India for India and the world. In this regard, he highlighted that the global share of personalised and precision technology platforms (such as antibody-drug conjugates, bi-specific antibodies, and cell and gene therapy) among the top-100 drugs by value is growing rapidly, from 5% in 2020 to 9% in 2025 and projected to grow to 20% by 2030. He also highlighted the 10 times increase in the number of Indian healthcare and life sciences startups over the last four years, from over 900 in 2020 to more than 10,000 in 2024, as well as the growing pipeline of innovative products of Indian firms.

Amit Agrawal said that the groundwork and the pipeline for projects for the PRIP scheme has been laid through this growing innovation ecosystem of Indian startups and industry, supported by a wide array of initiatives of the scientific Ministries/ Departments. The latter include the clinical trial network created by CSIR under its INTENT initiative; the patenting support available through DST's TIFAC and ICMR's Patent Mitra initiative; the handholding support available to both medical technology and drug innovations through ICMR's MedTech Mitra initiative; the funding support available to startups through Department of Biotechnology's BIRAC, MeitY's TIDE 2.0 and SAMRIDH schemes and DST's Quantum Computing Mission, etc.

Reiterating the Government's commitment to a robust research ecosystem, Amit said that PRIP is a transformative initiative aimed at catalysing innovation, strengthening industry-academia linkages, and positioning India as a global leader in pharmaceutical and MedTech research.

Prof. Abhay Karandikar, Secretary, DST underscored the importance of cutting-edge scientific research in driving advancements in pharmaceuticals and MedTech, reinforcing India's healthcare ecosystem and highlighted the supports available through the extensive incubator and accelerator network of DST.

S. Krishnan, Secretary, MeitY emphasised the transformative potential of digital health, artificial intelligence (AI) and data-driven technologies in drug discovery and medical device development. He highlighted the research strengths of MeitY's organisations, such as Society for Applied Microwave Electronics Engineering and Research (SAMEER), C-DAC and Centre for Materials for Electronics Technology (C-MET).

Dr Rajiv Bahl, Secretary, DHR and DG, ICMR highlighted the critical role of clinical research, indigenous drug development and regulatory advancements in accelerating pharmaceutical innovation. He offered the full support of the ICMR INTENT, MedTech Mitra and Patent Mitra initiatives in taking forward the shared goals of PRIP scheme. He also said that the industry-academia collaborative research window under the scheme could be of considerable help in taking forward the large volume of intramural and extramural research being funded by ICMR to the market with funding from PRIP and industry involvement.

Dr N. Kalaiselvi, Secretary, DSIR and DG, CSIR underscored the need to foster a culture of scientific collaboration between research institutions and industry to ensure the seamless translation of research into commercially viable applications. She highlighted that considerable research done in CSIR labs could be taken to the market through collaboration with industry and funding from PRIP.

The discussions reaffirmed the Government's vision of transforming India into a global hub for research and innovation in pharmaceuticals and medical technology. The workshop featured four dedicated breakout sessions, bringing together over 100 participants from leading scientific departments and premier institutions, including the National Institutes of Pharmaceutical Education and Research, IITs, CSIR labs and organisations of ICMR, MeitY, DST and Department of Bio technology, along with key government enablers for the ecosystem. Key deliberations covered the emerging trends in pharmaceutical and MedTech research, strategies for translating research into commercially viable products, government support mechanisms to accelerate sectoral growth and flexibilities sought to maximise the impact from the PRIP scheme.

All participants were requested to share their suggestions in the Expression of Interest (EoI) form for the PRIP scheme hosted on the website of the Department of Pharmaceuticals, so that these may be taken into account while taking forward the scheme and enabling participants. The EoI would be open till April 7, 2025.

TIOL CORP SEARCH

TIOL GROUP WEBSITES

taxindiaonline
taxindiainternational
tioltube
TKF
TIOLawards
A TIOL Website. Copyright © 2025 TIOLcorplaws.com All rights reserved.